A
Alnylam Pharmaceuticals, Inc. (ALNY)
NMS – Real Time Price. Currency in USD
317.36
-10.80 (-3.29%)
At close: Mar 27, 2026, 4:00 PM EDT
315.49
-1.87 (-0.59%)
After-hours: Mar 27, 2026, 7:01 PM EDT

NMS – Real Time Price. Currency in USD
317.36
-10.80 (-3.29%)
At close: Mar 27, 2026, 4:00 PM EDT
315.49
-1.87 (-0.59%)
After-hours: Mar 27, 2026, 7:01 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.76 | 6.05 | 10 | |
| Quick ratio | 2.71 | 5.63 | 10 | |
| Debt to Equity | 3.76 | 0.30 | 2.0 | |
| Debt to Assets | 0.59 | 1.04 | 4.0 | |
| Interest coverage | 1.02 | -16.91 | 4.0 | |
| Weighted average score | 6.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1.04B | 1.83B | 2.25B | 3.71B | 3.71B |
| Gross Profit | 869M | 1.52B | 1.92B | 3.03B | 3.03B |
| Operating Income | -785M | -282M | -177M | 502M | 502M |
| Net Income | -1.13B | -440M | -278M | 314M | 314M |
| EBITDA | -741M | -228M | -120M | 557M | 557M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 92.32 | 321.13 | 10 |
| Next quarter | 74.05 | 396.72 | 10 |
| Current year | 49.72 | 191.9 | 10 |
| Next year | 32.26 | 56.65 | 10 |
| Weighted average score | 10 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -12.16 | -25.74 | -55.42 | -55.17 | 1.0 |
| Y/Y | 84.95 | 322.56 | 226.15 | 235.19 | 10 |
| 3y average | 54.8 | 103.56 | 102.37 | 366.01 | 10 |
| 5y average | 51.72 | 55.74 | 56.29 | 221.57 | 10 |
| Weighted average score | 7.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Medium | 7.0 |
| Intangible assets | Medium | 7.0 |
| Switching costs | Medium | 6.0 |
| Network effect | Medium | 6.0 |
| Economies of scale | Medium | 7.0 |
| Weighted average score | 6.6 | |
Total debt $3.0B significantly exceeds cash reserves ($1.7B), raising financial stability concerns
Total current assets $4.1B exceed Total current liabilities $1.5B, highlighting excellent liquidity
Debt-to-equity ratio (3.8) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (1.0x) is dangerously low, suggesting debt repayment risks
The company generates positive free cash flow $140.3M, supporting its financial health